Cyclic bridged analogs of isoCA-4: Design, synthesis and biological evaluation.
Antineoplastic Agents
/ chemical synthesis
Cell Cycle Checkpoints
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cyclization
Drug Design
Humans
Molecular Docking Simulation
Neoplasms
/ drug therapy
Stilbenes
/ chemical synthesis
Tubulin
/ metabolism
Tubulin Modulators
/ chemical synthesis
Cancer
Combretastatin A-4
Pyridine
Quinaldine
Tubulin inhibitor
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
01 Jan 2021
01 Jan 2021
Historique:
received:
21
08
2020
revised:
21
09
2020
accepted:
21
09
2020
pubmed:
11
10
2020
medline:
21
4
2021
entrez:
10
10
2020
Statut:
ppublish
Résumé
In this work, a series of cyclic bridged analogs of isocombretastatin A-4 (isoCA-4) with phenyl or pyridine linkers were designed and synthesized. The synthesis of the desired analogs was performed by the formation of nitro-vinyl intermediates, followed by a Cadogan cyclization. Structure activity relationship (SAR) study demonstrates the critical role of the combination of quinaldine as ring A, pyridine as the linker, and indole as ring B in the same molecule, for the cytotoxic activity. Among all tested compounds, compound 42 showed the highest antiproliferative activity against a panel of cancer cell lines with average IC50 values of 5.6 nM. Also, compound 42 showed high antiproliferative activity against the MDR1-overexpressing K562R cell line; thus, it was 1.5- and 12-fold more active than the reference compounds, isoCA-4 and CA-4, respectively. Moreover, 42 displayed a strong antiproliferative activity against the colon-carcinoma cells (HT-29), which are resistant to combretastatin A-4 and isoCA-4, and it was found to be 8000-fold more active than natural CA-4. Compound 42 also effectively inhibited tubulin polymerization both in vitro and in cells, and induced cell cycle arrest in G2/M phase. Next, we demonstrated that compound 42 dose-dependently caused caspase-induced apoptosis of K562 cells through mitochondrial dysfunction. Finally, we evaluated the effect of compound 42 in human no cancer cells compared to the reference compound. We demonstrated that 42 was 73 times less cytotoxic than isoCA-4 in quiescent peripheral blood lymphocytes (PBLs). In summary, these results suggest that compound 42 represents a promising tubulin inhibitor worthy of further investigation.
Identifiants
pubmed: 33038796
pii: S0223-5234(20)30845-X
doi: 10.1016/j.ejmech.2020.112873
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Stilbenes
0
Tubulin
0
Tubulin Modulators
0
fosbretabulin
I5590ES2QZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112873Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.